Compared to non-carriers, HO carriers had more frequent ischemic heart disease (HO 46.7% vs WT 32.7%), CVD deaths (33.3% vs 27.2) and fewer stroke diagnoses (HO 20.0% vs WT 35.5%), corresponding well to the fact that TBC1D4 is expressed in heart and muscle tissue and not in the brain. This evidence concerns the gene TBC1D4 and coronary artery disorder.